CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2012-02-14): Tyrosine kinase inhibitors linked to increased treatment-related mortality

Drug & Device Development

Tyrosine kinase inhibitors linked to increased treatment-related mortality

Last Updated: 2012-02-14 15:30:02 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Drugs like sorafenib, sunitinib, and pazopanib - i.e., vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors - have improved cancer outcomes, but a new meta-analysis shows they also increase patients' risks for treatment-related fatalities.

"This is the second meta-analysis to implicate the inhibition of the VEGF pathway with an increased risk of FAEs (fatal adverse events) in patients with cancer," the researchers note. As they point out, the VEGF pathway is critical to several processes such as wound healing, cardiomyocyte homeostasis, and neovascularization.

For their study, reported online February 6 in the Journal of Clinical Oncology, Dr. Toni K. Choueiri with the Dana-Farber Cancer Institute in Boston, Massachusetts, and colleagues identified ten randomized controlled trials of pazopanib (Votrient), sunitinib (Sutent), or sorafenib (Nexavar) involving a total of 4679 patients

Overall, the rate of treatment-related fatal adverse events was 1.5% in patients receiving VEGFR TKIs, compared with 0.7% in control groups, which translated to a relative risk of 2.23 (p=0.023).

While the determination of treatment-related FAEs was likely somewhat subjective, the rate did not differ by tumor type or the agent being tested, the authors say.

Nonetheless, Dr. Choueiri and colleagues emphasize that the three drugs improve outcomes of patients with renal cell carcinoma, hepatocellular carcinoma and GI stromal tumor "and should continue to be offered to these patients."

"However," they conclude, "as this class of drugs gains greater clinical use, practitioners must be aware of the risks associated with their use and must provide rigorous monitoring to continue to improve patient outcomes."

SOURCE: http://bit.ly/zW3xlQ

J Clin Oncol 2012.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.